Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
1375117 | Bioorganic & Medicinal Chemistry Letters | 2010 | 5 Pages |
In pursuit of a potent and highly selective sphingosine-1-phosphate receptor agonists with an improved in vivo conversion of the precursor to the active phospho-drug, we have utilized previously reported phenylamide and phenylimidazole scaffolds to identify a selectivity enhancing moiety (SEM) and selectivity enhancing orientation (SEO) within both pharmacophores. SEM and SEO have allowed for over 100 to 500-fold improvement in selectivity for S1P receptor subtype 1 over subtype 3. Utility of SEM and SEO and further SAR study allowed for discovery of a potent and selective preclinical candidate PPI-4955 (21b) with an excellent in vivo potency and dose responsiveness and markedly improved overall in vivo pharmacodynamic properties upon oral administration.
Graphical abstractIdentification of a selectivity enhancing moiety has allowed for discovery of pro-drug PPI-4955 (21b), a potent and selective sphingosine-1-phosphate receptor-1 agonist, with excellent dose responsiveness and pharmacodynamic properties.Figure optionsDownload full-size imageDownload as PowerPoint slide